X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DF-003 is a potent small molecule inhibitor of ALPK1, which plays an important role in immunity and inflammation. It is under phase 1 clinical development for the treatment of ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) Syndrome.
Lead Product(s): 8-Bromo-pet-cyclic gmps
Therapeutic Area: Rare Diseases and Disorders Product Name: DF-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2024
Details:
DF-006 is a first-in-class innate immunity modulator that act as ALPK1 agonist, which is demonstrated treatment-naïve and virologically suppressed patients with chronic hepatitis B infection.
Lead Product(s): DF-006
Therapeutic Area: Infections and Infectious Diseases Product Name: DF-006
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
DF-003, discovered through Drug Farms’ IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), a key target regulating inflammation pathways that underly disease pathology in cardio-renal diseases.
Lead Product(s): 8-Bromo-pet-cyclic gmps
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DF-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
DF-003 is a highly potent first-in-class, oral investigational inhibitor of ALPK1 and the ALPK1 T237M driver mutation that causes disease in ROSAH syndrome patients.
Lead Product(s): 8-Bromo-pet-cyclic gmps
Therapeutic Area: Ophthalmology Product Name: DF-003
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
With the financing round, Drug Farm will continue its clinical program on DF-006 and advance DF-003 into a first-in-human clinical trial. DF-006 is a first-in-class, orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver.
Lead Product(s): DF-006
Therapeutic Area: Infections and Infectious Diseases Product Name: DF-006
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: YD Capital
Deal Size: $27.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 16, 2023
Details:
This funding will enable the Company to initiate human clinical trials with its lead drug DF-006, a first-in-class, orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases.
Lead Product(s): DF-006
Therapeutic Area: Infections and Infectious Diseases Product Name: DF-006
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: BioVeda China Fund
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
